Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.63 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.63 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 3/20 | 0.46 |
| ▸ | CTSD | P07339 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065655 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP9ALOX15BLM | |
| Hydrochloric Acid SCHEMBL23404089 | 0.98 | DPP4 (0.61) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL29499873 | 0.97 | DPP4 (0.59) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL29630514 | 0.92 | DPP4 (0.55) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL30193486 | 0.89 | DPP4 (0.52) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL31571449 | 0.89 | BACE1 (0.58) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL29777801 | 0.89 | DPP4 (0.52) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL8070748 | 0.88 | DPP4 (0.51) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL31031607 | 0.88 | BACE1 (0.54) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL29478400 | 0.88 | BACE1 (0.54) | DPP4DPP8DPP9ALOX15BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4676457-A1 | PROTECTIVE AMINOACID AGENTS FOR USE IN PERITONEAL DIALYSIS | Zytoprotec Flexible Kapitalgesellschaft (AT) | 2026-01-14 | — | — | EP | claimed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | claimed |
| EP-4551267-A1 | PERITONEAL DIALYSIS FLUID | Zytoprotec Flexible Kapitalgesellschaft (AT) | 2025-05-14 | — | — | EP | claimed |
| CN-118897023-B | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2025-03-25 | — | — | CN | claimed |
| CN-119104584-A | Diagnostic model and application thereof in diagnosis of aortic aneurysm | 首都医科大学附属北京友谊医院 | 2024-12-10 | — | — | CN | claimed |
| CN-118897023-A | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2024-11-05 | — | — | CN | claimed |
| WO-2024184220-A1 | PROTECTIVE AMINOACID AGENTS FOR USE IN PERITONEAL DIALYSIS | ZYTOPROTEC GMBH (AT) | 2024-09-12 | — | — | WO | claimed |
| EP-4424307-A1 | PROTECTIVE AGENT FOR USE IN PERITONEAL DIALYSIS | Zytoprotec GmbH (AT) | 2024-09-04 | — | — | EP | claimed |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2024-07-11 | — | — | US | claimed |
| WO-2016196743-A1 | METHODS AND SYSTEMS FOR DETECTING MELANOMA | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-12-08 | — | — | WO | claimed |
| US-20140142051-A1 | CARBOHYDRATE-BASED PERITONEAL DIALYSIS FLUID COMPRISING GLUTAMINE RESIDUE | ZYTOPROTEC GMBH (AT) | 2014-05-22 | — | — | US | claimed |
| EP-2640423-A1 | LIPOYL COMPOUNDS AND THEIR USE FOR TREATING ISCHEMIC INJURY | Ischemix LLC (US) | 2013-09-25 | — | — | EP | claimed |
| EP-2129370-B1 | Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue | ZYTOPROTEC GMBH (AT) | 2012-11-21 | — | — | EP | claimed |
| WO-2012067947-A1 | LIPOYL COMPOUNDS AND THEIR USE FOR TREATING ISCHEMIC INJURY | ISCHEMIX LLC (US) | 2012-05-24 | — | — | WO | claimed |
| US-20100099628-A1 | CARBOHYDRATE-BASED PERITONEAL DIALYSIS FLUID COMPRISING GLUTAMINE RESIDUE | ZYTO-PROTEC GMBH (AT) | 2010-04-22 | — | — | US | claimed |
| EP-2129370-A1 | CARBOHYDRATE-BASED PERITONEAL DIALYSIS FLUID COMPRISING GLUTAMINE RESIDUE | Zytoprotec Gmbh (AT) | 2009-12-09 | — | — | EP | claimed |
| WO-2008106702-A1 | CARBOHYDRATE-BASED PERITONEAL DIALYSIS FLUID COMPRISING GLUTAMINE RESIDUE | ZYTOPROTEC GMBH (AT) | 2008-09-12 | — | — | WO | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| US-4987123-A | L-ALANINE AND L-GLUTAMINE OR SALTS OR PEPTIDES THEREOF | AJINOMOTO CO., INC. (JP) | 1991-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | DPP4 1262/4885DPP8 3390/4885DPP9 2149/4885 |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | FOLR1, FOLR2, FRS2 | DPP4 4488/4885DPP8 3928/4885DPP9 3873/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | DPP4 2235/4885DPP8 3838/4885DPP9 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.